ArticleAntimicrobial agents and chemotherapy2011
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Engineering and physicochemical characterization of a novel, stable, symmetric bispecific antibody with dual target-binding using a common light chain.Protein science : a publication of the Protein Society · 2024Article
- Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy.Antibody therapeutics · 2024Article
- Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.Acta pharmacologica Sinica · 2023Article
- Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.Frontiers in drug delivery · 2023Article
- Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.Scientific reports · 2022Article
- Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography.Bioresources and bioprocessing · 2022Article
- HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.Clinical and translational medicine · 2022Article
- Current trends and challenges in the downstream purification of bispecific antibodies.Antibody therapeutics · 2021Review
- Article
- Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.Biomolecules · 2020Review
- Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules.mAbs · 2019Article
- Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies.Scientific reports · 2019Article
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2018Review
- Relative Contribution of Framework and CDR Regions in Antibody Variable Domains to Multimerisation of Fv- and scFv-Containing Bispecific Antibodies.Antibodies (Basel, Switzerland) · 2018Article
- A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6.PloS one · 2017Article
- Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells.Biological procedures online · 2017Article
- Engineering broadly neutralizing antibodies for HIV prevention and therapy.Advanced drug delivery reviews · 2016Review
- Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.Immunological reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we describe novel tetravalent, bispecific antibody derivatives that bind two different epitopes on the HIV coreceptor CCR5. The basic protein formats that we applied were derived from Morrison-type bispecific antibodies: whole IgGs to which we connected single-chain antibodies (scFvs) via (Gly4Ser)n sequences at either the C or N terminus of the light chain or heavy chain. By design optimization, including disulfide stabilization of scFvs or introduction of 30-amino-acid linkers, stable molecules could be obtained in amounts that were within the same range as or no less than 4-fold lower than those observed with monoclonal antibodies in transient expression assays. In contrast to monospecific CCR5 antibodies, bispecific antibody derivatives block two alternative docking sites of CCR5-tropic HIV strains on the CCR5 coreceptor. Consequently, these molecules showed 18- to 57-fold increased antiviral activities compared to the parent antibodies. Most importantly, one prototypic tetravalent CCR5 antibody had antiviral activity against virus strains resistant to the single parental antibodies. In summary, physical linkage of two CCR5 antibodies targeting different epitopes on the HIV coreceptor CCR5 resulted in tetravalent, bispecific antibodies with enhanced antiviral potency against wild-type and CCR5 antibody-resistant HIV-1 strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.